Surrozen, Inc./DE (SRZN)
Surrozen, Inc./DE (SRZN) from its SEC filings: 2025 revenue $3.5 million (-67% vs the year before), net margin -6961%, free cash flow -$30.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $3.5 million |
| Revenue growth | -67% |
| Net income | -$242.0 million |
| Net margin | -6960.8% |
| Free cash flow | -$30.4 million |
| Diluted EPS | $-32.37 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +409% |
| Cash | $102.0 million |
| Share count, 1 year | +37% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-11-08. Education only, not financial advice.